Article info

Download PDFPDF
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

Authors

  1. Address correspondence and reprint requests to: Gail L. Brown, MD, Telik, Inc., 3165 Porter Drive, Palo Alto, CA 94304, USA. Email: gbrown{at}telik.com

Citation

Kavanagh JJ, Gershenson DM, Choi H, et al
Multi-institutional phase 2 study of TLK286 (TELCYTA™, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

Publication history

  • First published June 1, 2005.
Online issue publication 
March 06, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.